Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.The company was formerly known as VEDANTRA PHARMACEUTICALS, INC. and changed its name to Elicio Therapeutics Inc. on September 18, 2019. The company was incorporated in 2011 and is headquartered in Boston, Massachusetts.
